Market
Novo Nordisk's global pharma revenue rank by end of 2025?
2
Resolution / Starting Odds
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Annual revenue reports from Novo Nordisk and industry ranking reports
Story
Novo Nordisk ($500B) Acquires Catalent for $16.5B to Boost Production of Wegovy, Ozempic
Dec 16, 2024, 04:02 AM
Novo Nordisk, valued at over $500 billion, is set to close its $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after the U.S. Federal Trade Commission (FTC) declined to challenge the deal. The acquisition, which also involves Novo Holdings taking over Catalent and Novo Nordisk acquiring three manufacturing sites from Novo Holdings, aims to address production capacity issues for Novo Nordisk's popular weight loss and diabetes drugs, Ozempic and Wegovy. Catalent, a subcontractor that already helps manufacture Wegovy, has been an attractive target due to its role in the pharmaceutical supply chain. The deal has received approval from both the European Commission and the FTC, following concerns about potential impacts on competition in the pharmaceutical industry. In addition to the acquisition, Novo Nordisk announced an investment of DKK 8.5 billion ($1.2 billion) in a new production facility in Odense, Denmark, to further expand its manufacturing capabilities for rare disease drugs.
View original story
Similar markets
Top 20 • 25%
Top 10 • 25%
Top 5 • 25%
Below Top 20 • 25%
Less than 5% • 25%
10% to 15% • 25%
More than 15% • 25%
5% to 10% • 25%
Top 3 in the sector • 25%
Leader in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Less than 30% • 25%
More than 50% • 25%
40% to 50% • 25%
30% to 40% • 25%
Growth above 10% • 25%
Growth below 5% • 25%
No growth • 25%
Growth 5-10% • 25%
No significant change • 25%
Increase by 1-5% • 25%
Increase by more than 5% • 25%
Decrease • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
AstraZeneca • 25%
Discontinue development • 25%
Partner with another company • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
$126 to $150 • 25%
Above $150 • 25%
Below $100 • 25%
$100 to $125 • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly > 60% • 25%
